Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Lampert Mark N
Relationship:   10% Owner
City:   San Francisco
State:   CA
   
Insider Summary:
  
   
Companies Owned :   44    
Direct Shares   110,838,010    

Indirect Shares

   88,557,834      
Direct Value   $1,424,811,955    

Indirect Value

   $1,621,009,022      
Total Shares   199,395,844      
Total Value   $3,045,820,978      


Repligen Corp $525,440,279 Dynavax Technologies Corp $68,309,353 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,652,421 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $165,431 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,783,247 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $26,817,195 Merus Nv $10,671,450 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $482,807 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $235,963,827 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,910,187 Structure Therapeutics Inc. $186,210,137 Engene Holdings Inc. $31,611,162 Allakos Inc. $19,901,704 Repligen Corp $525,440,279 Dynavax Technologies Corp $68,309,353 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,652,421 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $165,431 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,783,247 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $26,817,195 Merus Nv $10,671,450 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $482,807 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $235,963,827 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,910,187 Structure Therapeutics Inc. $186,210,137 Engene Holdings Inc. $31,611,162 Allakos Inc. $19,901,704
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    50   
    13    

     Stock price went up :
    40   
    4    
     Stock price went down :
    10   
    9    
   
     Gain/Loss Ratio :
   4.0   
   4.0   
     Percentage Gain/Loss :
   103.0%
 -82.1%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Arena Pharmaceuticals Inc ARNA Director, 10% Owner 2003-10-17 0 2003-10-17 4,520,212    Premium*  
            Repligen Corp RGEN 10% Owner 2009-05-15 3,216,850 0    Premium*  
            Dynavax Technologies Corp DVAX Indirect Beneficial Ow... 2009-06-19 6,193,051 2009-06-19 18,579,153    Premium*  
            Adolor Corp ADLR 10% Owner 2009-09-22 4,123,551 2009-09-22 12,370,653    Premium*  
            Gyre Therapeutics GYRE 10% Owner 0 2012-11-08 1,052,258    Premium*  
            Arqule Inc ARQL 10% Owner 2018-05-30 771,305 2010-04-05 12,624,219    Premium*  
            Astex Pharmaceuticals Inc ASTX 10% Owner 2010-04-20 5,583,399 2010-04-20 16,750,197    Premium*  
            Capstone Therapeutics Corp CAPS See Explanation of Res... 2011-06-27 0 2017-07-14 890,487    Premium*  
            Ligand Pharmaceuticals Inc LGND See Explanation of Res... 0 2014-03-25 130,175    Premium*  
            Icagen Inc ICGN 10% Owner 2011-09-07 0 2011-09-07 625,400    Premium*  
            Palatin Technologies Inc PTN 10% Owner 0 2014-02-27 2,494,521    Premium*  
            Neurocrine Biosciences Inc NBIX 10% Owner 2011-10-10 0 2011-10-12 3,527,700    Premium*  
            Kent International Inc KNTH See Explanation of Res... 2011-12-23 0 2011-12-23 0    Premium*  
            Chemocentryx, Inc. CCXI 10% Owner 0 2012-11-06 3,750,277    Premium*  
            Rigel Pharmaceuticals Inc RIGL 10% Owner 0 2013-06-07 7,761,738    Premium*  
            Cascadian Therapeutics, Inc CASC 10% Owner 2013-06-05 0 2015-02-05 1,898,293    Premium*  
            Tobira Therapeutics Inc TBRA See Explanation of Res... 0 2014-03-21 1,121,221    Premium*  
            Cti Biopharma Corporation CTIC See Explanation of Res... 2023-06-26 0 2023-06-26 0    Premium*  
            Infinity Pharmaceuticals Inc INFI 10% Owner 2021-02-11 534,847 2016-12-01 0    Premium*  
            XOMA Corporation XOMA Director, 10% Owner 2023-01-06 1,693,924 2023-01-06 361,774    Premium*  
            Alpine Immune Sciences Inc ALPN 10% Owner 2017-06-20 201,811 2017-05-09 0    Premium*  
            Glycomimetics Inc GLYC 10% Owner 2020-11-04 630,453 0    Premium*  
            Xenon Pharmaceuticals Inc. XENE 10% Owner 2018-03-27 59,464 2017-06-06 0    Premium*  
            Concert Pharmaceuticals, Inc. CNCE 10% Owner 2019-06-10 169,589 2017-10-19 0    Premium*  
            Syndax Pharmaceuticals Inc SNDX 10% Owner 2018-06-18 85,038 2018-06-18 0    Premium*  
            Immune Design Corp. IMDZ 10% Owner 2018-12-04 370,391 2018-12-04 0    Premium*  
            Pieris Pharmaceuticals, Inc. PIRS 10% Owner 2023-05-11 20,333,557 2019-01-30 0    Premium*  
            Calithera Biosciences, Inc. CALA 10% Owner 2020-05-21 480,432 0    Premium*  
            Five Prime Therapeutics Inc FPRX 10% Owner 2021-03-04 6,262,085 0    Premium*  
            Cytokinetics Inc CYTK See Explanation of Res... 2020-12-09 463,244 2019-12-10 0    Premium*  
            Merus Nv MRUS 10% Owner 2021-10-08 232,747 0    Premium*  
            Ideaya Biosciences, Inc. IDYA See Explanation of Res... 2021-02-02 233,150 2020-06-19 0    Premium*  
            Kymera Therapeutics, Inc. KYMR See Remarks and Footno... 2023-11-03 294,632 2020-08-21 0    Premium*  
            Eledon Pharmaceuticals Ord Shs ELDN 10% Owner 2024-05-09 220,460 0    Premium*  
            Olema Pharmaceuticals, Inc. OLMA Director, 10% Owner 2023-09-12 524,151 2023-09-14 99,556    Premium*  
            Cytomx Therapeutics, Inc. CTMX 10% Owner 2020-12-18 5,468,599 0    Premium*  
            Rain Therapeutics Inc. RAIN See Remarks; Former 10... 2024-01-25 0 2021-04-23 0    Premium*  
            Repare Therapeutics Inc. RPTX 10% Owner 2023-11-16 548,938 0    Premium*  
            Verastem, Inc. VSTM 10% Owner 2022-01-25 19,630,934 0    Premium*  
            ESSA Pharma Inc EPIX 10% Owner 2022-07-11 8,561,841 0    Premium*  
            Third Harmonic Bio, Inc. THRD 10% Owner 2022-12-20 241,309 2022-12-20 0    Premium*  
            Structure Therapeutics Inc. GPCR 10% Owner 2023-05-10 5,173,941 0    Premium*  
            Engene Holdings Inc. ENGN 10% Owner 2023-10-31 2,221,445 0    Premium*  
            Allakos Inc. ALLK 10% Owner 2024-01-16 16,312,872 0    Premium*  
* Premium Members only  

Records found :    356         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 11 of 15
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
KYMR Kymera Therapeutics, Inc. See Remarks and Footnotes   –       •      –    2022-05-27 4 B $14.78 $966,337 D/D 65,369 230,637 2.39 -
INFI Infinity Pharmaceuticals ... Director   –       •       •   2016-12-28 4 B $1.34 $986,805 D/D 738,848 698,623 3.92 -
CYTK Cytokinetics Inc 10% Owner   –       –       •   2019-12-11 4 B $9.52 $1,126,700 D/D 118,413 499,312 2.45 -
INFI Infinity Pharmaceuticals ... 10% Owner   –       –       •   2017-10-03 4 B $1.24 $1,169,047 D/D 946,597 727,541 2.45 -
ADLR Adolor Corp Direct Beneficial Owner   –       –       •   2009-07-13 4 S $1.67 $1,172,917 D/D (700,500) 5,492,551 0 -
FPRX Five Prime Therapeutics I... 10% Owner   –       –       •   2020-05-14 4 B $4.10 $1,203,707 D/D 293,587 541,084 2.45 %
MRUS Merus Nv 10% Owner   –       –       •   2020-01-13 4 B $14.98 $1,257,616 D/D 83,962 224,576 2.45 %
MRUS Merus Nv 10% Owner   –       –       •   2020-06-08 4 B $15.20 $1,326,261 D/D 87,254 345,371 2.45 %
KYMR Kymera Therapeutics, Inc. See Explanation of Responses   –       –      –    2022-01-31 4 B $40.70 $1,400,406 D/D 34,408 1,395,925 2.44 -
IDYA Ideaya Biosciences, Inc. 10% Owner   –       –       •   2020-06-19 4 B $14.39 $1,413,970 D/D 98,264 236,040 2.45 -
RPTX Repare Therapeutics Inc. 10% Owner   –       –       •   2023-11-16 4 B $5.38 $1,592,202 D/D 295,745 548,938 2.45 -
IMDZ Immune Design Corp. 10% Owner   –       –       •   2018-12-04 4 S $1.83 $1,653,907 D/D (902,000) 370,391 0 -
MRUS Merus Nv 10% Owner   –       –       •   2020-09-15 4 B $11.75 $1,724,360 D/D 146,754 382,784 2.45 %
FPRX Five Prime Therapeutics I... 10% Owner   –       –       •   2020-10-06 4 B $5.04 $1,738,288 D/D 345,241 566,223 2.45 %
CASC Cascadian Therapeutics, I... See Explanation of Responses   –       –      –    2014-07-16 4 D $3.24 $1,795,731 I/I (554,238) 2,412,290 0 -
MRUS Merus Nv 10% Owner   –       –       •   2021-03-22 4 B $22.75 $1,808,625 D/D 79,500 435,121 2.45 %
KNTH Kent International Inc See Explanation of Responses   –       –      –    2011-12-23 4 D $2.50 $1,814,015 I/I (725,606) 0 0 -
XOMA XOMA Corporation 10% Owner   –       –       •   2020-03-13 4 B $18.34 $1,834,090 D/D 100,000 1,247,676 2.45 %
RPTX Repare Therapeutics Inc. 10% Owner   –       –       •   2022-06-13 4 B $12.73 $1,898,820 D/D 149,161 412,604 2.45 -
KYMR Kymera Therapeutics, Inc. See Remarks and Footnotes   –       •      –    2022-05-06 4 B $19.26 $1,925,500 D/D 100,000 216,735 2.39 -
RAIN Rain Therapeutics Inc. 10% Owner   –       –       •   2021-05-21 4 B $15.94 $1,944,701 D/D 121,986 112,353 2.45 -
FPRX Five Prime Therapeutics I... 10% Owner   –       –       •   2019-10-07 4 B $3.75 $1,968,664 D/D 525,070 338,154 2.45 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-08 4 B $11.20 $1,969,663 I/I 175,800 1,354,736 1.5 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –      –    2014-03-25 4 S $69.95 $1,974,222 I/I (28,222) 130,175 0 -
INFI Infinity Pharmaceuticals ... 10% Owner   –       –       •   2018-11-19 4 B $1.35 $2,005,076 D/D 1,465,126 1,254,412 2.45 -
  356  Records found
  1   2   3   4   5   6   7   8   9   10   11  12   13   14   15      
  Page 11 of 15  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us